CoChat

Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial

Open access
Perez, Antonio, Carrasco-Sánchez, Francisco Javier, González, Carlos, Seguí-Ripoll, José Miguel, Trescolí, Carlos, Ena, Javier, Borrell, Mireia, Gomez Huelgas, Ricardo · 2020 · BMJ Open Diabetes Research & Care

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Abstract

Introduction: This study assessed the efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in insufficiently controlled people with type 2 diabetes. Research design and methods: COBALTA (for its acronym in Spanish, COntrol Basal durante la hospitalizacion y al ALTA) was a multicenter, open-label, single-arm, phase IV trial including 112 evaluable inpatients with type 2 diabetes insufficiently controlled (glycosylated hemoglobin (HbA1c) 8%–10%) with basal insulin and/or non-insulin antidiabetic drugs. Patients were treated with a basal–bolus–correction insulin regimen with Gla-300 during the hospitalization and with Gla-300 and/or non-insulin antidiabetics for 6 months after discharge. The primary endpoint was the HbA1c change from baseline to month 6 postdischarge. Results: HbA1c levels decreased from 8.8%±0.6% at baseline to 7.2%±1.1% at month 6 postdischarge (p<0.001, mean change 1.6%±1.1%). All 7-point blood glucose levels decreased from baseline to 24 hours predischarge (p≤0.001, mean changes from 25.1±66.6 to 63.0±85.4 mg/dL). Fasting plasma glucose also decreased from baseline to 24 hours predischarge (p<0.001), month 3 (p<0.001) and month 6 (p<0.001) postdischarge (mean changes 51.5±90.9, 68.2±96.0 and 77.6±86.4 mg/dL, respectively). Satisfaction was high and hyperglycemia/hypoglycemia perception was low according to the Diabetes Treatment Satisfaction Questionnaire at month 6 postdischarge. The incidence of confirmed (glucose<70 mg/dL)/severe hypoglycemia was 25.0% during hospitalization and 59.1% 6 months after discharge. No safety concerns were reported. Conclusions: Inpatient and intensification therapy at discharge with Gla-300 improved significantly glycemic control of patients with type 2 diabetes insufficiently controlled with other basal insulin and/or non-insulin antidiabetic medication, with high treatment satisfaction. Gla-300 could therefore be a treatment choice for hospital and postdischarge diabetes management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2020-001518

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 HbA1c levels (A) and FPG levels (B) during the study. *P≤0.001 vs baseline. FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin.
Figure 1 HbA1c levels (A) and FPG levels (B) during the study. *P≤0.001 vs baseline. FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin.CC BY-NC · PubMed Central
Figure 2 Seven-point blood glucose profile at baseline and 24 hours predischarge. *P≤0.001 vs baseline.
Figure 2 Seven-point blood glucose profile at baseline and 24 hours predischarge. *P≤0.001 vs baseline.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 2

  1. Perez Perez, 2012, [Consensus document on the management after hospital discharge of patient with hyperglycaemia], Med Clin, 138, 666 e1
  2. Giorda, 2014, Incidence and correlates of hypoglycemia in type 2 diabetes, The Hypos-1 Study. J Diabetes Metab, 5, 3

Cited by

See all 16

Metadata

Authors
Perez, A., Carrasco-Sánchez, F. J., González, C., Seguí-Ripoll, J. M., Trescolí, C., Ena, J., Borrell, M., & Gomez Huelgas, R.
Affiliations
  • Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universitat Autònoma de Barcelona, Barcelona, Spain
  • Hospital Juan Ramón Jiménez (ES)
  • Hospital Universitario 12 De Octubre (ES)
  • Department of Internal Medicine, Hospital Universitario San Joan d’Alacant, Sant Joan d'Alacant, Spain
  • Hospital de La Ribera (ES)
  • Hospital Marina Baixa (ES)
  • Sanofi (Spain) (ES)
  • Department of Internal Medicine, Hospital Regional Universitario de Málaga, Málaga, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga; CIBER Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2020-09
Volume
8
Issue
1
Pages
e001518
ISSN
2052-4897 (ISSN-L)
OpenAlex
W3086248874
Cited by
16
References
56
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 1
FWCI
1.89
Type
journal article
Language
en
Open access
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc)
Funders
Sanofi
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
insulin glargine 300 U/mL, type 2 diabetes, glycemic control, hospitalization, basal insulin, HbA1c, hypoglycemia, treatment satisfaction, post-discharge follow-up, non-insulin antidiabetic drugs, fasting blood glucose, blood glucose
MeSH terms
Insulin Glargine, Aftercare, Blood Glucose, Diabetes Mellitus, Type 2, Hospitalization, Humans, Patient Discharge

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial. https://app.cochat.ai/papers/10.1136/bmjdrc-2020-001518
The paper
Perez, A., Carrasco-Sánchez, F. J., González, C., Seguí-Ripoll, J. M., Trescolí, C., Ena, J., Borrell, M., & Gomez Huelgas, R. (2020). Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2020-001518

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.